Clinical trial · Interventional
Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy
Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy
NCT01435200CI-TRIAL-00025734completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenous iron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intravenous iron
- description
- Iron sucrose 200 mg intravenous infusion in 15 minutes
- interventionNames
- Drug: Intravenous iron
- type
- PLACEBO_COMPARATOR
- label
- Oral iron
- description
- Ferrous fumarate 200 mg oral three times a day
- interventionNames
- Drug: Intravenous iron
Primary outcomes (1)
- measure
- Red blood cell (RBC) transfusion rate
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age 20-70 years * Good performance status (Zubrod score \< 2) * No serious underlying disease * Normal renal function test * Normal liver function test * Platinum based chemotherapy is the first line regimen * No prior or receiving radiotherapy Exclusion Criteria: * Iron hypersensitivity * Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia * Progressive disease * Bone marrow metastasis
References
Publications (1)
- DERIVEDAthibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013 Dec;131(3):679-82. doi: 10.1016/j.ygyno.2013.09.028. Epub 2013 Oct 5. PMID 24099839